Top

Published in:

Open Access 01-04-2023 | Multiple Myeloma | Original Paper

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells

Authors: Beihui Huang, Huixin Liu, Szehoi Chan, Junru Liu, Jingli Gu, Meilan Chen, Lifen Kuang, Xiaozhe Li, Xingding Zhang, Juan Li

Published in: Medical Oncology | Issue 4/2023

Abstract

RUNX2 is a transcription factor that participates in osteoblast differentiation and chondrocyte maturation and plays an important role in the invasion and metastasis of cancers. With the deepening of research, evidence has indicated the correlation between RUNX2 and bone destruction in cancers. However, the mechanisms underlying its role in multiple myeloma remain unclear. By observing the induction effects of conditioned medium from myeloma cells on preosteoblasts (MC3T3-E1) and preosteoclasts (RAW264.7) and constructing myeloma-bearing mice, we found that RUNX2 promotes bone destruction in multiple myeloma. In vitro, conditioned medium from RUNX2-overexpressing myeloma cells reduced osteoblast activity and increased osteoclast activity. In vivo, RUNX2 expression was positively correlated with bone loss in myeloma-bearing mice. These results suggest that therapeutic inhibition of RUNX2 may protect against bone destruction by maintaining the balance between osteoblast and osteoclast activity in multiple myeloma.

Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–36. https://doi.org/10.1016/j.soncn.2017.05.012.CrossRefPubMed

Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58–60. https://doi.org/10.7861/clinmedicine.19-1-58.CrossRefPubMed

Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–81. https://doi.org/10.1053/j.seminoncol.2016.11.004.CrossRefPubMedPubMedCentral

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–57. https://doi.org/10.1200/JCO.2012.47.7901.CrossRefPubMedPubMedCentral

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7. https://doi.org/10.1038/s41408-017-0037-4.CrossRefPubMedPubMedCentral

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, et al. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76(5):1089–100. https://doi.org/10.1158/0008-5472.CAN-15-1703.CrossRefPubMedPubMedCentral

Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G, Rinaldi E, Curci P, Liso V, Passeri G, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1(6):e27. https://doi.org/10.1038/bcj.2011.22.CrossRefPubMedPubMedCentral

van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063–75. https://doi.org/10.1038/s41375-019-0404-1.CrossRefPubMedPubMedCentral

Komori T. Molecular mechanism of Runx2-dependent bone development. Mol Cells. 2020;43(2):168–75. https://doi.org/10.14348/molcells.2019.0244.CrossRefPubMedPubMedCentral

10.

Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018;149(4):313–23. https://doi.org/10.1007/s00418-018-1640-6.CrossRefPubMed

11.

Zhao W, Yang H, Chai J, Xing L. RUNX2 as a promising therapeutic target for malignant tumors. Cancer Manag Res. 2021;13:2539–48. https://doi.org/10.2147/cmar.S302173.CrossRefPubMedPubMedCentral

12.

Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci. 2010;101(12):2670–5. https://doi.org/10.1111/j.1349-7006.2010.01742.x.CrossRefPubMed

13.

Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer. 2010;10:202. https://doi.org/10.1186/1471-2407-10-202.CrossRefPubMedPubMedCentral

14.

Pranavkrishna S, Sanjeev G, Akshaya RL, Rohini M, Selvamurugan N. Regulation of Runx2 and Its signaling pathways by MicroRNAs in breast cancer metastasis. Curr Protein Pept Sci. 2021;22(7):534–47. https://doi.org/10.2174/1389203721666201116115337.CrossRefPubMed

15.

Yang DP, Lu HP, Chen G, Yang J, Gao L, Song JH, Chen SW, Mo JX, Kong JL, Tang ZQ, et al. Integrated expression analysis revealed RUNX2 upregulation in lung squamous cell carcinoma tissues. IET Syst Biol. 2020;14(5):252–60. https://doi.org/10.1049/iet-syb.2020.0063.CrossRefPubMedPubMedCentral

16.

Senbanjo LT, AlJohani H, AlQranei M, Majumdar S, Ma T, Chellaiah MA. Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells. Cancer Drug Resist. 2020;3(3):586–602. https://doi.org/10.20517/cdr.2020.21.CrossRefPubMedPubMedCentral

17.

Zhang X, Akech J, Browne G, Russell S, Wixted JJ, Stein JL, Stein GS, Lian JB. Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer. 2015;136(6):1321–32. https://doi.org/10.1002/ijc.29094.CrossRefPubMed

18.

Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS, Feng YM. ITGBL1 Is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway. Cancer Res. 2015;75(16):3302–13. https://doi.org/10.1158/0008-5472.Can-15-0240.CrossRefPubMed

19.

Kim B, Kim H, Jung S, Moon A, Noh DY, Lee ZH, Kim HJ, Kim HH. A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J Bone Miner Res. 2020;35(1):155–66. https://doi.org/10.1002/jbmr.3869.CrossRefPubMed

20.

Trotter TN, Li M, Pan Q, Peker D, Rowan PD, Li J, Zhan F, Suva LJ, Javed A, Yang Y. Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood. 2015;125(23):3598–608. https://doi.org/10.1182/blood-2014-12-613968.CrossRefPubMedPubMedCentral

21.

Gowda PS, Wildman BJ, Trotter TN, Xu X, Hao X, Hassan MQ, Yang Y. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. Mol Cancer Res. 2018;16(7):1138–48. https://doi.org/10.1158/1541-7786.Mcr-17-0606.CrossRefPubMedPubMedCentral

22.

Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-osteoclast communication and bone homeostasis. Cells. 2020. https://doi.org/10.3390/cells9092073.CrossRefPubMedPubMedCentral

23.

Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39(1):19–26. https://doi.org/10.1007/s00774-020-01162-6.CrossRefPubMed

24.

Veeriah V, Zanniti A, Paone R, Chatterjee S, Rucci N, Teti A, Capulli M. Interleukin-1β, lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk. Sci Rep. 2016;6:29880. https://doi.org/10.1038/srep29880.CrossRefPubMedPubMedCentral

25.

McDonald MM, Kim AS, Mulholland BS, Rauner M. New insights into osteoclast biology. JBMR Plus. 2021;5(9):e10539. https://doi.org/10.1002/jbm4.10539.CrossRefPubMedPubMedCentral

26.

Li H, Zhou RJ, Zhang GQ, Xu JP. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol. 2013;34(3):1807–12. https://doi.org/10.1007/s13277-013-0720-4.CrossRefPubMed

27.

Sase T, Suzuki T, Miura K, Shiiba K, Sato I, Nakamura Y, Takagi K, Onodera Y, Miki Y, Watanabe M, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer. 2012;131(10):2284–93. https://doi.org/10.1002/ijc.27525.CrossRefPubMed

28.

Jiang ZY, Jiang JJ, Ma YS, Li HY, Shi W, Fu PL, Xu CF, Lu JZ, Fu D, Xu JG. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway. Biochem Biophys Res Commun. 2018;505(4):1003–9. https://doi.org/10.1016/j.bbrc.2018.10.025.CrossRefPubMed

29.

Zong JC, Wang X, Zhou X, Wang C, Chen L, Yin LJ, He BC, Deng ZL. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice. Oncol Rep. 2016;35(2):739–48. https://doi.org/10.3892/or.2015.4430.CrossRefPubMed

30.

Wang Q, Yu W, Huang T, Zhu Y, Huang C. RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression. Oncol Rep. 2016;36(5):2777–84. https://doi.org/10.3892/or.2016.5101.CrossRefPubMed

31.

Li XQ, Lu JT, Tan CC, Wang QS, Feng YM. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. Cancer Lett. 2016;380(1):78–86. https://doi.org/10.1016/j.canlet.2016.06.007.CrossRefPubMed

32.

Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med J. 2016;52(1):12–7. https://doi.org/10.4068/cmj.2016.52.1.12.CrossRefPubMedPubMedCentral

33.

Yeo CE, Kang WY, Seong SJ, Cho S, Lee HW, Yoon YR, Kim HJ. Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF/c-Fms/D-type cyclins. Exp Cell Res. 2017;359(1):112–9. https://doi.org/10.1016/j.yexcr.2017.08.003.CrossRefPubMed

34.

Dong W, Yu J, Qi M, Bai Y, Liang R, Chen H. Effects of M-CSF concentration, RANKL concentration and M-CSF preinduction on osteoclastogenesis. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010;27(6):1336–40.PubMed

35.

De Vries TJ, Schoenmaker T, Aerts D, Grevers LC, Souza PP, Nazmi K, van de Wiel M, Ylstra B, Lent PL, Leenen PJ, et al. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone. J Cell Physiol. 2015;230(1):210–25. https://doi.org/10.1002/jcp.24702.CrossRefPubMed

36.

Kurotaki D, Yoshida H, Tamura T. Epigenetic and transcriptional regulation of osteoclast differentiation. Bone. 2020;138:115471. https://doi.org/10.1016/j.bone.2020.115471.CrossRefPubMed

37.

Tucci M, De Palma R, Lombardi L, Rodolico G, Berrino L, Dammacco F, Silvestris F. Beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res. 2009;69(16):6738–46. https://doi.org/10.1158/0008-5472.Can-09-0949.CrossRefPubMed

38.

Kovacheva M, Zepp M, Berger S, Berger MR. Conditional knockdown of integrin beta-3 reveals its involvement in osteolytic and soft tissue lesions of breast cancer skeletal metastasis. J Cancer Res Clin Oncol. 2021;147(2):361–71. https://doi.org/10.1007/s00432-020-03428-y.CrossRefPubMed

39.

Gupta A, Cao W, Chellaiah MA. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol Cancer. 2012;11:66. https://doi.org/10.1186/1476-4598-11-66.CrossRefPubMedPubMedCentral

40.

Santiago-Sánchez GS, Pita-Grisanti V, Quiñones-Díaz B, Gumpper K, Cruz-Monserrate Z, Vivas-Mejía PE. Biological functions and therapeutic potential of Lipocalin 2 in cancer. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21124365.CrossRefPubMedPubMedCentral

41.

Courbon G, Francis C, Gerber C, Neuburg S, Wang X, Lynch E, Isakova T, Babitt JL, Wolf M, Martin A, et al. Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Res. 2021;9(1):35. https://doi.org/10.1038/s41413-021-00154-0.CrossRefPubMedPubMedCentral

42.

Zhang S, Kaplan FS, Shore EM. Different roles of GNAS and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res. 2012;44(10):724–31. https://doi.org/10.1055/s-0032-1321845.CrossRefPubMedPubMedCentral

43.

Abdallah BM, Alzahrani AM, Kassem M. Secreted Clusterin protein inhibits osteoblast differentiation of bone marrow mesenchymal stem cells by suppressing ERK1/2 signaling pathway. Bone. 2018;110:221–9. https://doi.org/10.1016/j.bone.2018.02.018.CrossRefPubMed

44.

Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8(11):105. https://doi.org/10.1038/s41408-018-0139-7.CrossRefPubMedPubMedCentral

Title: RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
Authors: Beihui Huang
Huixin Liu
Szehoi Chan
Junru Liu
Jingli Gu
Meilan Chen
Lifen Kuang
Xiaozhe Li
Xingding Zhang
Juan Li
Publication date: 01-04-2023
Publisher: Springer US
Keyword: Multiple Myeloma
Published in: Medical Oncology / Issue 4/2023
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-01960-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors

Role of epigenetics in OSCC: an understanding above genetics

PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer

CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor

Investigation of the effect of rhamnetin on mice injected with solid and ehrlich ascites tumor

Adjuvant treatment of surgically treated bone metastasis patients: association with hospital characteristics and trends over time

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials